论文部分内容阅读
一、国外发展概况美国Eli Lilly研究所Chauvette在头孢氨苄合成法改进研究过程中,因3-位结合氯原子化合物合成效率被确认,同时发现3-位氯代化合物确有优异抗菌作用,因而合成多种3-位氯代头孢烯酸的7-位衍生物,其中得到口服吸收、抗菌作用良好的头孢克罗(Cefaclor),代号为Lilly99638,化学名为3-氯-7-d-(2-苯甘氨酰胺)-3-头孢烯-4-羧酸.该公司于1975年进行开发,1978年9月在英国
First, the foreign development profile Eli Lilly Institute of the United States Chauvette Cefalexin synthesis in the improvement of the research process, due to 3-position combination of chlorine atom compound synthesis efficiency was confirmed, also found that 3-position chlorinated compounds do have excellent antibacterial activity, and thus synthetic A variety of 7-position derivatives of 3-position chlorocephemisiacs, wherein cefaclor, which is orally absorbed and has good antibacterial activity, is given as Lilly 99638 and has a chemical name of 3-chloro-7-d- (2 -phenylglycinamide) -3-cephem-4-carboxylic acid The company was developed in 1975 and in September 1978 in the United Kingdom